CellTivity Scientific, Inc.
- Industry
- Medical Devices
- Founded Year
- 2016
- Headquarters
- 133 Boston Post Road, Weston, MA 02493, USA
- Employee Count
- 10
Key People
- Jean-Michel Fallet - CEO
- Dr. Jean-Luc Fraikin - Chief Scientific Officer
Assessment
- Team
-
Aspect: First-time 10+ yrs
Summary: Leadership with over a decade of experience in relevant fields.
The CEO and CSO bring over ten years of experience in their respective fields, providing a solid foundation for strategic decision-making and innovation within the company.
- Clinical Need
-
Aspect: Very Strong
Summary: High demand for real-time, intraprocedural cancer diagnostics.
The company's Dynamic Cell Imaging (DCI) technology meets a significant clinical need by providing real-time, intraprocedural cancer diagnostics, which can lead to more timely and accurate treatment decisions.
- Competition
-
Aspect: First mover
Summary: Pioneering real-time metabolic biopsy assessments.
As a pioneer in real-time metabolic biopsy assessments, the company has the opportunity to set industry standards and build strong brand recognition before competitors enter the market.
- Technical Challenge
-
Aspect: Complex
Summary: Developing non-invasive, real-time imaging technology.
Creating a non-invasive, real-time imaging system that accurately visualizes cellular metabolism without staining or tissue destruction involves significant technical hurdles, including ensuring image clarity, system reliability, and integration into existing clinical workflows.
- Patent
-
Aspect: Strong
Summary: Robust intellectual property portfolio.
The company has secured multiple patents covering its Dynamic Cell Imaging technology, safeguarding its innovations and potentially deterring competitors from developing similar technologies.
- Financing
-
Aspect: Medium
Summary: Secured funding from notable investors.
The company has received investments from organizations like the Massachusetts Life Sciences Center and MassVentures, providing a solid financial foundation. However, further funding rounds may be necessary to support growth and commercialization efforts.
- Regulatory
-
Aspect: Pivotal Trial
Summary: Advancing through pivotal clinical trials.
The company is currently conducting pivotal clinical trials to demonstrate the safety and efficacy of its technology. Navigating the regulatory landscape is critical, and any delays or challenges in obtaining approvals could impact the timeline for product launch.
Opportunity Rollup
- Odds of Success
- 3.7
- Peak Market Share
- 5.25
- Segment CAGR
- 8.3%
- Market Segment
- Diagnostic Imaging
- Market Sub Segment
- Live Cell Imaging
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.26 |
| 2 | 0.79 |
| 3 | 1.84 |
| 4 | 3.68 |
| 5 | 5.25 |
Key Takeaway
CellTivity Scientific's innovative DCI technology addresses a critical need in real-time cancer diagnostics, positioning the company favorably in a growing market despite technical and regulatory challenges.